Published in Arthritis Res on May 09, 2002
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest (2005) 2.91
Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol (2016) 2.36
Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest (2004) 2.16
Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer (2010) 2.04
Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov (2012) 1.91
T cells as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 1.75
STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One (2011) 1.61
JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab (2012) 1.56
Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med (2006) 1.49
Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus (2004) 1.43
Comparison of Anti-inflammatory Activities of Six Curcuma Rhizomes: A Possible Curcuminoid-independent Pathway Mediated by Curcuma phaeocaulis Extract. Evid Based Complement Alternat Med (2006) 1.35
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis (2011) 1.28
Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res (2011) 1.23
Activation of AMP-activated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes (2009) 1.23
Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther (2009) 1.22
Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther (2011) 1.21
Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci U S A (2009) 1.20
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer (2010) 1.18
Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev (2010) 1.18
Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc Natl Acad Sci U S A (2008) 1.15
Immunology and homeopathy. 3. Experimental studies on animal models. Evid Based Complement Alternat Med (2006) 1.14
Regulation of epithelium-specific Ets-like factors ESE-1 and ESE-3 in airway epithelial cells: potential roles in airway inflammation. Cell Res (2008) 1.13
Developments in the clinical understanding of rheumatoid arthritis. Arthritis Res Ther (2009) 1.10
Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol (2012) 1.06
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS One (2009) 1.06
TIM-3: a novel regulatory molecule of alloimmune activation. J Immunol (2010) 1.05
Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain. Proc Natl Acad Sci U S A (2002) 1.04
Campylobacter jejuni drives MyD88-independent interleukin-6 secretion via Toll-like receptor 2. Infect Immun (2009) 1.04
Identification of co-expression gene networks, regulatory genes and pathways for obesity based on adipose tissue RNA Sequencing in a porcine model. BMC Med Genomics (2014) 1.02
IL-6 controls susceptibility to helminth infection by impeding Th2 responsiveness and altering the Treg phenotype in vivo. Eur J Immunol (2013) 1.01
The varying faces of IL-6: From cardiac protection to cardiac failure. Cytokine (2015) 0.98
Differential cytokine mRNA expression in heterophils isolated from Salmonella-resistant and -susceptible chickens. Immunology (2004) 0.98
Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine (2011) 0.98
B-cell-targeted therapies in systemic lupus erythematosus. Cell Mol Immunol (2013) 0.97
Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol (2013) 0.96
Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by dietary flavonols in the polyp prevention trial. Cancer Prev Res (Phila) (2010) 0.93
Strategies to design and analyze targeted sequencing data: cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Targeted Sequencing Study. Circ Cardiovasc Genet (2014) 0.93
Cellular immunotherapy: antigen recognition is just the beginning. Springer Semin Immunopathol (2005) 0.92
Thyrotropin regulates IL-6 expression in CD34+ fibrocytes: clear delineation of its cAMP-independent actions. PLoS One (2013) 0.92
Tumor hypoxia enhances Non-Small Cell Lung Cancer metastasis by selectively promoting macrophage M2 polarization through the activation of ERK signaling. Oncotarget (2014) 0.91
IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro. J Bone Miner Metab (2014) 0.90
Role of miRNA let-7 and its major targets in prostate cancer. Biomed Res Int (2014) 0.89
Update on Targets of Biologic Therapies for Rheumatoid Arthritis. Curr Rheumatol Rev (2008) 0.89
Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum Cardiovascular Diabetes (ABCD) cohort study. Cardiovasc Diabetol (2013) 0.87
Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD. Clin J Am Soc Nephrol (2014) 0.86
Mesenchymal stem/progenitors and other endometrial cell types from women with polycystic ovary syndrome (PCOS) display inflammatory and oncogenic potential. J Clin Endocrinol Metab (2013) 0.86
Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10. Cytokine (2015) 0.85
The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int (2010) 0.85
CD8 regulates T regulatory cell production of IL-6 and maintains their suppressive phenotype in allergic lung disease. J Immunol (2010) 0.85
Genome-wide interaction analysis reveals replicated epistatic effects on brain structure. Neurobiol Aging (2014) 0.84
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs (2014) 0.84
Interleukin-6 and risk of colorectal cancer: results from the CLUE II cohort and a meta-analysis of prospective studies. Cancer Causes Control (2015) 0.84
Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor. Anticancer Agents Med Chem (2012) 0.84
Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis (2006) 0.84
An association study between genetic polymorphism in the interleukin-6 receptor gene and coronary heart disease. Biomed Res Int (2014) 0.83
Anti-allergic activity of a platycodon root ethanol extract. Int J Mol Sci (2010) 0.83
Early administration of IL-6RA does not prevent radiation-induced lung injury in mice. Radiat Oncol (2010) 0.82
Interleukin-6, vascular endothelial growth factor and transforming growth factor beta 1 in canine steroid responsive meningitis-arteritis. BMC Vet Res (2013) 0.82
Biomarkers of Inflammation and Immune Function and Risk of Colorectal Cancer. Curr Colorectal Cancer Rep (2015) 0.82
CXCL8 and CCL20 Enhance Osteoclastogenesis via Modulation of Cytokine Production by Human Primary Osteoblasts. PLoS One (2015) 0.81
The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells. Inflammation (2013) 0.81
Expression level of the growth factor progranulin is related with development of systemic lupus erythematosus. Diagn Pathol (2013) 0.81
Role of interleukin-6 in immune complex induced models of vascular injury. Inflammation (2005) 0.80
Pleiotropic effects of statins in atrial fibrillation patients: the evidence. Vasc Health Risk Manag (2009) 0.80
Skewed production of IL-6 and TGFβ by cultured salivary gland epithelial cells from patients with Sjögren's syndrome. PLoS One (2012) 0.80
Diagnostic and Prognostic Value of Serum Interleukin-6 in Colorectal Cancer. Medicine (Baltimore) (2016) 0.80
Fatal hemorrhage induced by subtilase cytotoxin from Shiga-toxigenic Escherichia coli. Microb Pathog (2011) 0.80
Tumor necrosis factor-α induces expression and release of interleukin-6 by human urothelial cells. Inflamm Res (2010) 0.80
Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody. PLoS One (2009) 0.80
Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. Rheumatol Int (2012) 0.79
New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol (2016) 0.79
Interleukin-6: a therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases. Gut (2010) 0.79
Toxicogenomics of subchronic hexachlorobenzene exposure in Brown Norway rats. Environ Health Perspect (2004) 0.79
Biologic treatments for systemic rheumatic diseases. Oral Dis (2008) 0.79
A study on the effect of IL-6 gene polymorphism on the prognosis of non-small-cell lung cancer. Onco Targets Ther (2015) 0.79
The roles of catabolic factors in the development of osteoarthritis. Tissue Eng Part B Rev (2013) 0.79
Higher level of IL-6 in Jaccoud's arthropathy secondary to systemic lupus erythematosus: a perspective for its treatment? Rheumatol Int (2014) 0.78
The role of interleukin-6 in malignant mesothelioma. Transl Lung Cancer Res (2015) 0.78
Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients. J Korean Med Sci (2014) 0.78
FcγR-driven release of IL-6 by macrophages requires NOX2-dependent production of reactive oxygen species. J Biol Chem (2013) 0.78
Upregulation of inflammatory gene transcripts in periosteum of chronic migraineurs: Implications for extracranial origin of headache. Ann Neurol (2016) 0.78
Toxocara canis mucins among other excretory-secretory antigens induce in vitro secretion of cytokines by mouse splenocytes. Parasitol Res (2015) 0.78
Procalcitonin beyond the acute phase: novel biomediator properties? BMC Med (2013) 0.77
Effects of obesity on the association between long-term sleep apnea treatment and changes in interleukin-6 levels: the Icelandic Sleep Apnea Cohort. J Sleep Res (2014) 0.77
Colonization properties of Campylobacter jejuni in chickens. Eur J Microbiol Immunol (Bp) (2012) 0.77
The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol (2009) 0.76
Heterogeneity among septic shock patients in a set of immunoregulatory markers. Eur J Clin Microbiol Infect Dis (2013) 0.76
Characterization, promoter analysis and expression of the interleukin-6 gene in blunt snout bream, Megalobrama amblycephala. Fish Physiol Biochem (2016) 0.76
A new synthetic varacin analogue, 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153), decreased hereditary catalepsy and increased the BDNF gene expression in the hippocampus in mice. Psychopharmacology (Berl) (2011) 0.76
Upregulated expression level of the growth factor, progranulin, is associated with the development of primary Sjögren's syndrome. Exp Ther Med (2014) 0.76
Subgingival microbiota dysbiosis in systemic lupus erythematosus: association with periodontal status. Microbiome (2017) 0.75
Reversal of tubo-ovarian atypical epithelial patterns after cessation of ovarian stimulation by letrozole. Int J Exp Pathol (2016) 0.75
Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients. J Immunol Res (2015) 0.75
Immunomodulatory effects of ethanol extract of germinated ice plant (Mesembryanthemum crystallinum). Lab Anim Res (2017) 0.75
Exercise Training Attenuates the Dysregulated Expression of Adipokines and Oxidative Stress in White Adipose Tissue. Oxid Med Cell Longev (2017) 0.75
Polymorphisms in the IL-6 and IL-6R receptor genes as new diagnostic biomarkers of acute appendicitis: a study on two candidate genes in pediatric patients with acute appendicitis. Ital J Pediatr (2015) 0.75
Inflammation and epstein-barr virus infection are common features of myasthenia gravis thymus: possible roles in pathogenesis. Autoimmune Dis (2011) 0.75
Enrofloxacin and Toltrazuril Are Able to Reduce Toxoplasma gondii Growth in Human BeWo Trophoblastic Cells and Villous Explants from Human Third Trimester Pregnancy. Front Cell Infect Microbiol (2017) 0.75
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (1994) 26.02
Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science (1994) 11.33
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev (1991) 11.10
Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (1986) 9.63
Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A (1987) 9.26
A family of cytokine-inducible inhibitors of signalling. Nature (1997) 9.22
A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J (1990) 9.17
Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem (1995) 8.52
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell (1994) 6.45
A new protein containing an SH2 domain that inhibits JAK kinases. Nature (1997) 6.28
Structure and function of a new STAT-induced STAT inhibitor. Nature (1997) 6.02
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 5.72
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60
Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science (1992) 5.18
Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 5.06
Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science (1988) 4.93
Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science (1995) 4.90
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol (1998) 4.74
Specific inhibition of Stat3 signal transduction by PIAS3. Science (1997) 4.74
Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum (1988) 4.60
Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med (1987) 4.58
IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP. Cell (1990) 4.58
Interleukin-6 family of cytokines and gp130. Blood (1995) 4.52
Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A (1998) 4.38
SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell (1999) 4.29
Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J (1986) 4.24
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A (1998) 4.12
Differentiation and proliferation of hematopoietic stem cells. Blood (1993) 4.02
Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A (1987) 3.92
Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity (1996) 3.66
Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. Eur J Biochem (1986) 3.63
SOCS proteins: negative regulators of cytokine signaling. Stem Cells (2001) 3.40
A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J (1996) 3.40
Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol (1993) 3.37
Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci (1994) 3.36
B-cell-stimulatory factor 2 (beta 2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells. Proc Natl Acad Sci U S A (1987) 3.33
Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci U S A (1991) 3.31
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A (1993) 3.29
Cytokine receptors and signal transduction. Annu Rev Immunol (1992) 3.27
Cytokine signaling through nonreceptor protein tyrosine kinases. Science (1995) 3.16
SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell (1999) 3.15
Negative regulation of cytokine signaling pathways. Annu Rev Immunol (2000) 2.98
Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. J Biol Chem (1983) 2.97
B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med (1988) 2.88
Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A (1989) 2.87
Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J (1999) 2.80
STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci U S A (1996) 2.64
A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J (1995) 2.52
Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun (1997) 2.51
Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci U S A (1998) 2.48
T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J Immunol (1981) 2.46
Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett (1989) 2.43
Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett (1988) 2.39
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood (2000) 2.31
Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci U S A (1998) 2.31
cDNA cloning of murine interleukin-HP1: homology with human interleukin 6. Eur J Immunol (1988) 2.26
Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. J Immunol (1982) 2.26
Gigantism in mice lacking suppressor of cytokine signalling-2. Nature (2000) 2.25
SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell (1999) 2.19
T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor. J Exp Med (1988) 2.14
SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem (2000) 2.14
Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci U S A (2001) 2.09
Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J (1996) 2.07
Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis (1993) 2.05
Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A (1995) 2.05
Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells. FEBS Lett (1987) 2.04
Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem Biophys Res Commun (1997) 1.97
Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int (1993) 1.96
Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity (2000) 1.92
IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol (1988) 1.92
Regulation of very primitive, multipotent, hemopoietic cells by hemopoietin-1. Cell (1986) 1.89
Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol (1989) 1.89
Hepatocyte-stimulating factor III shares structural and functional identity with leukemia-inhibitory factor. J Immunol (1989) 1.87
Functional domains of the granulocyte colony-stimulating factor receptor. EMBO J (1991) 1.82
Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res (1993) 1.77
Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc Natl Acad Sci U S A (1994) 1.74
Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci U S A (1989) 1.69
In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. Blood (1989) 1.68
Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts. Proc Natl Acad Sci U S A (2000) 1.65
Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol (1993) 1.62
Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells. J Biol Chem (1987) 1.60
Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. Proc Natl Acad Sci U S A (1991) 1.60
Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J Exp Med (2001) 1.55
Purification and NH2-terminal sequence of a plasmacytoma growth factor derived from the murine macrophage cell line P388D1. J Immunol (1987) 1.55
Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol (1997) 1.53
SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo. Immunity (2001) 1.47
The myeloid blood cell differentiation-inducing protein MGI-2A is interleukin-6. Blood (1988) 1.47
Human T cell activation with phytohemagglutinin. The function of IL-6 as an accessory signal. J Immunol (1988) 1.46
Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood (1989) 1.40
Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. J Immunol (1992) 1.40
IL-6 cytokine family and signal transduction: a model of the cytokine system. J Mol Med (Berl) (1996) 1.37
Rapid enhancement of beta 2-interferon/B-cell differentiation factor BSF-2 gene expression in human fibroblasts by diacylglycerols and the calcium ionophore A23187. Proc Natl Acad Sci U S A (1987) 1.36
Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha. Blood (1988) 1.35
Enhancement of the interleukin 2 receptor expression on T cells by multiple B-lymphotropic lymphokines. Immunol Lett (1987) 1.35
Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol (1998) 1.31
Functional and biochemical association of Hck with the LIF/IL-6 receptor signal transducing subunit gp130 in embryonic stem cells. EMBO J (1994) 1.27
Recombinant human interleukin 6 (B-cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (M1). FEBS Lett (1988) 1.23
Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. Trends Biochem Sci (1999) 1.23
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood (2005) 4.29
Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol (2006) 4.10
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis (2007) 4.05
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (2004) 3.92
IL-6: regulator of Treg/Th17 balance. Eur J Immunol (2010) 3.82
SOCS-1 participates in negative regulation of LPS responses. Immunity (2002) 3.39
Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci U S A (2008) 3.34
Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum (2003) 3.29
The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest (2005) 2.91
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 2.75
Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2005) 2.64
IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2008) 2.60
Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A (2010) 2.46
IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci U S A (2007) 2.46
Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J Exp Med (2009) 2.02
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res (2010) 1.84
Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol (2011) 1.76
Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol (2004) 1.70
Impaired colonization of the gonads by primordial germ cells in mice lacking a chemokine, stromal cell-derived factor-1 (SDF-1). Proc Natl Acad Sci U S A (2003) 1.69
Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol (2003) 1.69
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia (2013) 1.58
IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A (2002) 1.55
Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum (2008) 1.55
Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol (2011) 1.52
Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol (2004) 1.52
Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum (2009) 1.51
Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther (2005) 1.48
Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum (2008) 1.43
Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc Natl Acad Sci U S A (2002) 1.42
Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT. Proc Natl Acad Sci U S A (2005) 1.39
Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine (2002) 1.34
Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem (2001) 1.33
Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration. Hepatology (2005) 1.33
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. Mod Rheumatol (2011) 1.33
The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol (2010) 1.30
Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci (2012) 1.27
Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol (2009) 1.25
Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett (2002) 1.25
Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice. Int Immunol (2008) 1.20
Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci U S A (2009) 1.20
Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer (2006) 1.19
iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis (2009) 1.19
A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus eyrthematosus in Japanese. PLoS Genet (2012) 1.17
The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr Opin Rheumatol (2011) 1.17
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis (2012) 1.13
Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease. J Gastroenterol (2002) 1.13
Underexpression of mitochondrial-DNA encoded ATP synthesis-related genes and DNA repair genes in systemic lupus erythematosus. Arthritis Res Ther (2011) 1.13
Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol (2008) 1.12
STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc Res (2005) 1.11
Aryl hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster promotes interleukin-17-producing T-helper cell differentiation. Proc Natl Acad Sci U S A (2013) 1.09
A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol (2007) 1.09
The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) (2010) 1.08
The roles of aryl hydrocarbon receptor in immune responses. Int Immunol (2013) 1.08
Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res (2007) 1.07
Aryl hydrocarbon receptor deficiency in T cells suppresses the development of collagen-induced arthritis. Proc Natl Acad Sci U S A (2011) 1.07
Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett (2011) 1.06
Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol (2011) 1.06
Demonstration of cooperative contribution of MET- and EGFR-mediated STAT3 phosphorylation to liver regeneration by exogenous suppressor of cytokine signalings. J Hepatol (2007) 1.06
Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res (2010) 1.05
Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung. J Pathol (2003) 1.05
The biology and medical implications of interleukin-6. Cancer Immunol Res (2014) 1.05
The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther (2008) 1.04
Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine. Cytokine (2007) 1.02
The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther (2005) 1.02
Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. Proc Natl Acad Sci U S A (2013) 1.02
A regulatory role for suppressor of cytokine signaling-1 in T(h) polarization in vivo. Int Immunol (2002) 1.01
Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes (2007) 1.00
Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol (2004) 0.99
Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis. J Rheumatol (2004) 0.99
Characteristics of fracture and related factors in patients with rheumatoid arthritis. Mod Rheumatol (2008) 0.99
Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol (2010) 0.98
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood (2002) 0.98
Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol (2011) 0.98
Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study. Arthritis Rheum (2006) 0.98
A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol (2011) 0.96
Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells. Int Immunol (2007) 0.96
Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci (2011) 0.95
Signals through gp130 upregulate Wnt5a and contribute to cell adhesion in cardiac myocytes. FEBS Lett (2004) 0.95
SOCS-1 suppresses TNF-alpha-induced apoptosis through the regulation of Jak activation. Int Immunol (2004) 0.95
An association analysis of HLA-DRB1 with systemic lupus erythematosus and rheumatoid arthritis in a Japanese population: effects of *09:01 allele on disease phenotypes. Rheumatology (Oxford) (2013) 0.93
Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol (2011) 0.93
Interactions among type I and type II interferon, tumor necrosis factor, and beta-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus. Arthritis Res Ther (2009) 0.93
Cytokine networks in systemic lupus erythematosus. J Biomed Biotechnol (2010) 0.93